Perioperative administration of sub-anesthetic ketamine/esketamine for preventing postpartum depression symptoms: A trial sequential meta-analysis
Postpartum depression (PPD) is a major mental health issue affecting 10%-15% of women globally. This meta-analysis synthesized updated evidence on sub-anesthetic ketamine/esketamine's efficacy in preventing PPD. Randomized controlled trials (RCTs) comparing ketamine/esketamine to a placebo for...
Saved in:
| Published in | PloS one Vol. 19; no. 11; p. e0310751 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
18.11.2024
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1932-6203 1932-6203 |
| DOI | 10.1371/journal.pone.0310751 |
Cover
Loading…
| Abstract | Postpartum depression (PPD) is a major mental health issue affecting 10%-15% of women globally. This meta-analysis synthesized updated evidence on sub-anesthetic ketamine/esketamine's efficacy in preventing PPD.
Randomized controlled trials (RCTs) comparing ketamine/esketamine to a placebo for PPD prevention were searched without language restriction. Primary outcomes were PPD risk at 1- and 4-6-week postpartum. Secondary outcomes included the difference in depression scores and risk of adverse events. Trial sequential analysis (TSA) was conducted to validate the reliability.
A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3-0.57) and 4-6-week (RR, 0.47; 95%CI, 0.35-0.63) follow-ups. Consistently, participants receiving ketamine/esketamine had lower depression-related scores at 1- (standardized mean difference [SMD], -0.94; 95%CI, -1.26 to -0.62) and 4-6-week (SMD, -0.89; 95%CI, -1.25 to -0.53) follow-ups. Despite potential publication bias, TSA confirmed the evidence's reliability. Subgroup analysis showed that ketamine/esketamine's preventive effect on 1-week PPD was consistent, regardless of administration timing, type of agents, or total dosage (<0.5 vs. ≥0.5 mg/kg). For the 4-6-week period, PPD risk was favorably reduced only with postoperative administration or the use of esketamine, with the total dosage having no observed influence. Participants on ketamine/esketamine experienced more frequency of hallucinations (RR, 4.77; 95%CI, 1.39-16.44) and dizziness (RR, 1.36; 95%CI, 1.02-1.81).
Our findings advocate for the postoperative administration of low-dose ketamine/esketamine to avert PPD, which needed additional research for confirmation. |
|---|---|
| AbstractList | ObjectivePostpartum depression (PPD) is a major mental health issue affecting 10%–15% of women globally. This meta-analysis synthesized updated evidence on sub-anesthetic ketamine/esketamine’s efficacy in preventing PPD.MethodsRandomized controlled trials (RCTs) comparing ketamine/esketamine to a placebo for PPD prevention were searched without language restriction. Primary outcomes were PPD risk at 1- and 4–6-week postpartum. Secondary outcomes included the difference in depression scores and risk of adverse events. Trial sequential analysis (TSA) was conducted to validate the reliability.ResultsA meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3–0.57) and 4–6-week (RR, 0.47; 95%CI, 0.35–0.63) follow-ups. Consistently, participants receiving ketamine/esketamine had lower depression-related scores at 1- (standardized mean difference [SMD], −0.94; 95%CI, −1.26 to −0.62) and 4–6-week (SMD, −0.89; 95%CI, −1.25 to −0.53) follow-ups. Despite potential publication bias, TSA confirmed the evidence’s reliability. Subgroup analysis showed that ketamine/esketamine’s preventive effect on 1-week PPD was consistent, regardless of administration timing, type of agents, or total dosage (<0.5 vs. ≥0.5 mg/kg). For the 4–6-week period, PPD risk was favorably reduced only with postoperative administration or the use of esketamine, with the total dosage having no observed influence. Participants on ketamine/esketamine experienced more frequency of hallucinations (RR, 4.77; 95%CI, 1.39–16.44) and dizziness (RR, 1.36; 95%CI, 1.02–1.81).ConclusionOur findings advocate for the postoperative administration of low-dose ketamine/esketamine to avert PPD, which needed additional research for confirmation. Postpartum depression (PPD) is a major mental health issue affecting 10%-15% of women globally. This meta-analysis synthesized updated evidence on sub-anesthetic ketamine/esketamine's efficacy in preventing PPD.OBJECTIVEPostpartum depression (PPD) is a major mental health issue affecting 10%-15% of women globally. This meta-analysis synthesized updated evidence on sub-anesthetic ketamine/esketamine's efficacy in preventing PPD.Randomized controlled trials (RCTs) comparing ketamine/esketamine to a placebo for PPD prevention were searched without language restriction. Primary outcomes were PPD risk at 1- and 4-6-week postpartum. Secondary outcomes included the difference in depression scores and risk of adverse events. Trial sequential analysis (TSA) was conducted to validate the reliability.METHODSRandomized controlled trials (RCTs) comparing ketamine/esketamine to a placebo for PPD prevention were searched without language restriction. Primary outcomes were PPD risk at 1- and 4-6-week postpartum. Secondary outcomes included the difference in depression scores and risk of adverse events. Trial sequential analysis (TSA) was conducted to validate the reliability.A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3-0.57) and 4-6-week (RR, 0.47; 95%CI, 0.35-0.63) follow-ups. Consistently, participants receiving ketamine/esketamine had lower depression-related scores at 1- (standardized mean difference [SMD], -0.94; 95%CI, -1.26 to -0.62) and 4-6-week (SMD, -0.89; 95%CI, -1.25 to -0.53) follow-ups. Despite potential publication bias, TSA confirmed the evidence's reliability. Subgroup analysis showed that ketamine/esketamine's preventive effect on 1-week PPD was consistent, regardless of administration timing, type of agents, or total dosage (<0.5 vs. ≥0.5 mg/kg). For the 4-6-week period, PPD risk was favorably reduced only with postoperative administration or the use of esketamine, with the total dosage having no observed influence. Participants on ketamine/esketamine experienced more frequency of hallucinations (RR, 4.77; 95%CI, 1.39-16.44) and dizziness (RR, 1.36; 95%CI, 1.02-1.81).RESULTSA meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3-0.57) and 4-6-week (RR, 0.47; 95%CI, 0.35-0.63) follow-ups. Consistently, participants receiving ketamine/esketamine had lower depression-related scores at 1- (standardized mean difference [SMD], -0.94; 95%CI, -1.26 to -0.62) and 4-6-week (SMD, -0.89; 95%CI, -1.25 to -0.53) follow-ups. Despite potential publication bias, TSA confirmed the evidence's reliability. Subgroup analysis showed that ketamine/esketamine's preventive effect on 1-week PPD was consistent, regardless of administration timing, type of agents, or total dosage (<0.5 vs. ≥0.5 mg/kg). For the 4-6-week period, PPD risk was favorably reduced only with postoperative administration or the use of esketamine, with the total dosage having no observed influence. Participants on ketamine/esketamine experienced more frequency of hallucinations (RR, 4.77; 95%CI, 1.39-16.44) and dizziness (RR, 1.36; 95%CI, 1.02-1.81).Our findings advocate for the postoperative administration of low-dose ketamine/esketamine to avert PPD, which needed additional research for confirmation.CONCLUSIONOur findings advocate for the postoperative administration of low-dose ketamine/esketamine to avert PPD, which needed additional research for confirmation. Objective Postpartum depression (PPD) is a major mental health issue affecting 10%-15% of women globally. This meta-analysis synthesized updated evidence on sub-anesthetic ketamine/esketamine's efficacy in preventing PPD. Methods Randomized controlled trials (RCTs) comparing ketamine/esketamine to a placebo for PPD prevention were searched without language restriction. Primary outcomes were PPD risk at 1- and 4-6-week postpartum. Secondary outcomes included the difference in depression scores and risk of adverse events. Trial sequential analysis (TSA) was conducted to validate the reliability. Results A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3-0.57) and 4-6-week (RR, 0.47; 95%CI, 0.35-0.63) follow-ups. Consistently, participants receiving ketamine/esketamine had lower depression-related scores at 1- (standardized mean difference [SMD], -0.94; 95%CI, -1.26 to -0.62) and 4-6-week (SMD, -0.89; 95%CI, -1.25 to -0.53) follow-ups. Despite potential publication bias, TSA confirmed the evidence's reliability. Subgroup analysis showed that ketamine/esketamine's preventive effect on 1-week PPD was consistent, regardless of administration timing, type of agents, or total dosage (<0.5 vs. [greater than or equal to]0.5 mg/kg). For the 4-6-week period, PPD risk was favorably reduced only with postoperative administration or the use of esketamine, with the total dosage having no observed influence. Participants on ketamine/esketamine experienced more frequency of hallucinations (RR, 4.77; 95%CI, 1.39-16.44) and dizziness (RR, 1.36; 95%CI, 1.02-1.81). Conclusion Our findings advocate for the postoperative administration of low-dose ketamine/esketamine to avert PPD, which needed additional research for confirmation. Postpartum depression (PPD) is a major mental health issue affecting 10%-15% of women globally. This meta-analysis synthesized updated evidence on sub-anesthetic ketamine/esketamine's efficacy in preventing PPD. Randomized controlled trials (RCTs) comparing ketamine/esketamine to a placebo for PPD prevention were searched without language restriction. Primary outcomes were PPD risk at 1- and 4-6-week postpartum. Secondary outcomes included the difference in depression scores and risk of adverse events. Trial sequential analysis (TSA) was conducted to validate the reliability. A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3-0.57) and 4-6-week (RR, 0.47; 95%CI, 0.35-0.63) follow-ups. Consistently, participants receiving ketamine/esketamine had lower depression-related scores at 1- (standardized mean difference [SMD], -0.94; 95%CI, -1.26 to -0.62) and 4-6-week (SMD, -0.89; 95%CI, -1.25 to -0.53) follow-ups. Despite potential publication bias, TSA confirmed the evidence's reliability. Subgroup analysis showed that ketamine/esketamine's preventive effect on 1-week PPD was consistent, regardless of administration timing, type of agents, or total dosage (<0.5 vs. [greater than or equal to]0.5 mg/kg). For the 4-6-week period, PPD risk was favorably reduced only with postoperative administration or the use of esketamine, with the total dosage having no observed influence. Participants on ketamine/esketamine experienced more frequency of hallucinations (RR, 4.77; 95%CI, 1.39-16.44) and dizziness (RR, 1.36; 95%CI, 1.02-1.81). Our findings advocate for the postoperative administration of low-dose ketamine/esketamine to avert PPD, which needed additional research for confirmation. Objective Postpartum depression (PPD) is a major mental health issue affecting 10%–15% of women globally. This meta-analysis synthesized updated evidence on sub-anesthetic ketamine/esketamine’s efficacy in preventing PPD. Methods Randomized controlled trials (RCTs) comparing ketamine/esketamine to a placebo for PPD prevention were searched without language restriction. Primary outcomes were PPD risk at 1- and 4–6-week postpartum. Secondary outcomes included the difference in depression scores and risk of adverse events. Trial sequential analysis (TSA) was conducted to validate the reliability. Results A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3–0.57) and 4–6-week (RR, 0.47; 95%CI, 0.35–0.63) follow-ups. Consistently, participants receiving ketamine/esketamine had lower depression-related scores at 1- (standardized mean difference [SMD], −0.94; 95%CI, −1.26 to −0.62) and 4–6-week (SMD, −0.89; 95%CI, −1.25 to −0.53) follow-ups. Despite potential publication bias, TSA confirmed the evidence’s reliability. Subgroup analysis showed that ketamine/esketamine’s preventive effect on 1-week PPD was consistent, regardless of administration timing, type of agents, or total dosage (<0.5 vs. ≥0.5 mg/kg). For the 4–6-week period, PPD risk was favorably reduced only with postoperative administration or the use of esketamine, with the total dosage having no observed influence. Participants on ketamine/esketamine experienced more frequency of hallucinations (RR, 4.77; 95%CI, 1.39–16.44) and dizziness (RR, 1.36; 95%CI, 1.02–1.81). Conclusion Our findings advocate for the postoperative administration of low-dose ketamine/esketamine to avert PPD, which needed additional research for confirmation. ObjectivePostpartum depression (PPD) is a major mental health issue affecting 10%-15% of women globally. This meta-analysis synthesized updated evidence on sub-anesthetic ketamine/esketamine's efficacy in preventing PPD.MethodsRandomized controlled trials (RCTs) comparing ketamine/esketamine to a placebo for PPD prevention were searched without language restriction. Primary outcomes were PPD risk at 1- and 4-6-week postpartum. Secondary outcomes included the difference in depression scores and risk of adverse events. Trial sequential analysis (TSA) was conducted to validate the reliability.ResultsA meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3-0.57) and 4-6-week (RR, 0.47; 95%CI, 0.35-0.63) follow-ups. Consistently, participants receiving ketamine/esketamine had lower depression-related scores at 1- (standardized mean difference [SMD], -0.94; 95%CI, -1.26 to -0.62) and 4-6-week (SMD, -0.89; 95%CI, -1.25 to -0.53) follow-ups. Despite potential publication bias, TSA confirmed the evidence's reliability. Subgroup analysis showed that ketamine/esketamine's preventive effect on 1-week PPD was consistent, regardless of administration timing, type of agents, or total dosage (<0.5 vs. ≥0.5 mg/kg). For the 4-6-week period, PPD risk was favorably reduced only with postoperative administration or the use of esketamine, with the total dosage having no observed influence. Participants on ketamine/esketamine experienced more frequency of hallucinations (RR, 4.77; 95%CI, 1.39-16.44) and dizziness (RR, 1.36; 95%CI, 1.02-1.81).ConclusionOur findings advocate for the postoperative administration of low-dose ketamine/esketamine to avert PPD, which needed additional research for confirmation. Postpartum depression (PPD) is a major mental health issue affecting 10%-15% of women globally. This meta-analysis synthesized updated evidence on sub-anesthetic ketamine/esketamine's efficacy in preventing PPD. Randomized controlled trials (RCTs) comparing ketamine/esketamine to a placebo for PPD prevention were searched without language restriction. Primary outcomes were PPD risk at 1- and 4-6-week postpartum. Secondary outcomes included the difference in depression scores and risk of adverse events. Trial sequential analysis (TSA) was conducted to validate the reliability. A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3-0.57) and 4-6-week (RR, 0.47; 95%CI, 0.35-0.63) follow-ups. Consistently, participants receiving ketamine/esketamine had lower depression-related scores at 1- (standardized mean difference [SMD], -0.94; 95%CI, -1.26 to -0.62) and 4-6-week (SMD, -0.89; 95%CI, -1.25 to -0.53) follow-ups. Despite potential publication bias, TSA confirmed the evidence's reliability. Subgroup analysis showed that ketamine/esketamine's preventive effect on 1-week PPD was consistent, regardless of administration timing, type of agents, or total dosage (<0.5 vs. ≥0.5 mg/kg). For the 4-6-week period, PPD risk was favorably reduced only with postoperative administration or the use of esketamine, with the total dosage having no observed influence. Participants on ketamine/esketamine experienced more frequency of hallucinations (RR, 4.77; 95%CI, 1.39-16.44) and dizziness (RR, 1.36; 95%CI, 1.02-1.81). Our findings advocate for the postoperative administration of low-dose ketamine/esketamine to avert PPD, which needed additional research for confirmation. |
| Audience | Academic |
| Author | Hung, Kuo-Chuan Chen, Jen-Yin Kao, Chia-Li Chen, I-Wen Lin, Chien-Hung Lin, Chien-Ming Ko, Ching-Chung Lai, Yi-Chen |
| AuthorAffiliation | 4 Department of Medical Imaging, Chi Mei Medical Center, Tainan City, Taiwan 3 School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan NYU Grossman School of Medicine: New York University School of Medicine, UNITED STATES OF AMERICA 1 Department of Anesthesiology, Chi Mei Medical Center, Tainan City, Taiwan 2 Department of Anesthesiology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan 5 Department of Health and Nutrition, Chia Nan University of Pharmacy and Science, Tainan City, Taiwan |
| AuthorAffiliation_xml | – name: 1 Department of Anesthesiology, Chi Mei Medical Center, Tainan City, Taiwan – name: 4 Department of Medical Imaging, Chi Mei Medical Center, Tainan City, Taiwan – name: 2 Department of Anesthesiology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan – name: 3 School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan – name: 5 Department of Health and Nutrition, Chia Nan University of Pharmacy and Science, Tainan City, Taiwan – name: NYU Grossman School of Medicine: New York University School of Medicine, UNITED STATES OF AMERICA |
| Author_xml | – sequence: 1 givenname: Kuo-Chuan surname: Hung fullname: Hung, Kuo-Chuan – sequence: 2 givenname: Chia-Li surname: Kao fullname: Kao, Chia-Li – sequence: 3 givenname: Yi-Chen surname: Lai fullname: Lai, Yi-Chen – sequence: 4 givenname: Jen-Yin surname: Chen fullname: Chen, Jen-Yin – sequence: 5 givenname: Chien-Hung surname: Lin fullname: Lin, Chien-Hung – sequence: 6 givenname: Ching-Chung surname: Ko fullname: Ko, Ching-Chung – sequence: 7 givenname: Chien-Ming surname: Lin fullname: Lin, Chien-Ming – sequence: 8 givenname: I-Wen orcidid: 0009-0004-7122-6901 surname: Chen fullname: Chen, I-Wen |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39556562$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk9uK2zAQhk3Z0j20b1BaQ6G0F8lKVizZe1PC0kNgYUtPt0KWx4m2tuXVyKF5jT5x5U1S4mUpxRcej7_5RzOaOY2OWttCFD2nZEqZoOc3tnetqqddcE8Jo0Sk9FF0QnOWTHhC2NGBfRydIt4QkrKM8yfRMcvTlKc8OYl-fwZnbAdOebOGWJWNaQ364dO2sa1i7IuJagH9CrzR8U_wKiBwDrg348q6uHOwhtabdhl3Fn2nnO-buITgRxykcNN03jZ4Ec9j74yqY4TbfggJZhOkQhZVb9Dg0-hxpWqEZ7v3WfT9w_tvl58mV9cfF5fzq4nmOfMTnZEiE0IUouQFAa0IYQVLRQEZECiFyBJR5QrSsswTXmpWKE6J4gmA0Gk1Y2fRy61uV1uUu3aiZDTJ81mWcxKIxZYorbqRnTONchtplZF3DuuWMtRpdA1yxhSojOsiYTCbQaayrORAywQUqSpGg9a7Xba-aKDUoXKn6pHo-E9rVnJp15LSVLCEDud9s1NwNnQOvWwMaqjrcD22Hw7OSLjrhPGAvrqHPlzejlqqUIFpKxsS60FUzjPKBSNpIgI1fYAKTwmN0WH4KhP8o4C3o4DAePjll6pHlIuvX_6fvf4xZl8fsCtQtV-hrfthUnEMvjhs9d8e76c-ABdbQDuL6KCS2vi7iQ-lmVpSIocV2zdNDismdysWgmf3gvf6_wz7AwyIL5E |
| CitedBy_id | crossref_primary_10_1016_j_jpsychires_2025_02_021 crossref_primary_10_1186_s13643_025_02807_1 |
| Cites_doi | 10.1007/s00737-005-0096-6 10.1192/bjp.150.6.782 10.25122/jml-2020-0116 10.1016/j.jad.2023.07.103 10.1016/j.conb.2017.04.011 10.1097/MD.0000000000033086 10.1080/03630242.2015.1101737 10.1136/bmj.l4898 10.1016/j.jad.2023.07.007 10.1146/annurev-med-041217-011106 10.1016/j.bcp.2020.113935 10.1186/s12884-014-0402-2 10.1111/j.1600-0447.2009.01363.x 10.1016/j.jclinepi.2011.06.004 10.1016/j.jpsychires.2022.04.037 10.1016/j.jad.2017.12.013 10.1001/jamapsychiatry.2023.0069 10.1016/j.ijsu.2021.105906 10.1016/j.psychres.2023.115165 10.1186/s12884-022-05118-8 10.1186/s12871-022-01588-7 10.1016/S0140-6736(14)61276-9 10.1016/j.jclinepi.2008.10.009 10.1111/jdi.14024 10.3389/fpsyt.2022.1038379 10.1176/appi.ajp.2020.20081251 10.1136/bmj.39489.470347.AD 10.1001/jama.2015.18948 10.1007/s00431-021-04289-4 10.1097/MD.0000000000032010 10.1016/j.psychres.2022.114396 10.1016/j.jad.2024.01.202 10.1016/j.jad.2022.10.020 10.1371/journal.pone.0195365 10.1186/s12888-023-05017-y 10.1056/NEJMoa2304145 10.1007/s00404-017-4334-8 10.1111/jocn.16121 10.1111/pcn.12902 10.1186/s12871-019-0910-8 10.1002/brb3.1715 10.1016/j.psychres.2019.03.026 |
| ContentType | Journal Article |
| Copyright | Copyright: © 2024 Hung et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. COPYRIGHT 2024 Public Library of Science 2024 Hung et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2024 Hung et al 2024 Hung et al 2024 Hung et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: Copyright: © 2024 Hung et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. – notice: COPYRIGHT 2024 Public Library of Science – notice: 2024 Hung et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2024 Hung et al 2024 Hung et al – notice: 2024 Hung et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0310751 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Health Research Premium Collection (ProQuest) Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agriculture Science Database ProQuest Health & Medical Collection Proquest Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Agricultural Science Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Ketamine/esketamine for postpartum depression |
| EISSN | 1932-6203 |
| ExternalDocumentID | 3129948960 oai_doaj_org_article_43aea86cb23e44e8a88d6e1d2ea0ff31 PMC11573214 A816730527 39556562 10_1371_journal_pone_0310751 |
| Genre | Meta-Analysis Journal Article |
| GeographicLocations | Taiwan |
| GeographicLocations_xml | – name: Taiwan |
| GrantInformation_xml | – fundername: ; grantid: CMOR11102 |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM ADRAZ BBORY CGR CUY CVF ECM EIF IPNFZ NPM RIG PMFND 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI RC3 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c693t-c80b8777b7d6b0eca003b357be8e0ed77827f9ae5dd926dc3ba610a62ee7c5f43 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Wed Aug 13 01:18:04 EDT 2025 Wed Aug 27 01:23:35 EDT 2025 Thu Aug 21 18:30:09 EDT 2025 Mon Jul 21 11:16:25 EDT 2025 Fri Jul 25 11:20:04 EDT 2025 Tue Jun 17 21:56:04 EDT 2025 Tue Jun 10 20:59:40 EDT 2025 Fri Jun 27 05:14:21 EDT 2025 Fri Jun 27 05:14:09 EDT 2025 Thu May 22 21:23:27 EDT 2025 Thu Apr 03 07:09:27 EDT 2025 Thu Apr 24 23:09:03 EDT 2025 Tue Jul 01 01:40:54 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| License | Copyright: © 2024 Hung et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c693t-c80b8777b7d6b0eca003b357be8e0ed77827f9ae5dd926dc3ba610a62ee7c5f43 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 Competing Interests: The authors have declared that no competing interests exist. |
| ORCID | 0009-0004-7122-6901 |
| OpenAccessLink | https://doaj.org/article/43aea86cb23e44e8a88d6e1d2ea0ff31 |
| PMID | 39556562 |
| PQID | 3129948960 |
| PQPubID | 1436336 |
| PageCount | e0310751 |
| ParticipantIDs | plos_journals_3129948960 doaj_primary_oai_doaj_org_article_43aea86cb23e44e8a88d6e1d2ea0ff31 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11573214 proquest_miscellaneous_3130203236 proquest_journals_3129948960 gale_infotracmisc_A816730527 gale_infotracacademiconefile_A816730527 gale_incontextgauss_ISR_A816730527 gale_incontextgauss_IOV_A816730527 gale_healthsolutions_A816730527 pubmed_primary_39556562 crossref_citationtrail_10_1371_journal_pone_0310751 crossref_primary_10_1371_journal_pone_0310751 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-11-18 |
| PublicationDateYYYYMMDD | 2024-11-18 |
| PublicationDate_xml | – month: 11 year: 2024 text: 2024-11-18 day: 18 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2024 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | J Power (pone.0310751.ref010) 2023 RC Boyd (pone.0310751.ref055) 2005; 8 JH Ma (pone.0310751.ref017) 2019; 279 S Farías-Antúnez (pone.0310751.ref009) 2018; 228 W Wang (pone.0310751.ref038) 2023; 39 JAC Sterne (pone.0310751.ref028) 2019; 366 L Pan (pone.0310751.ref025) 2023; 14 JL Cox (pone.0310751.ref057) 1987; 150 E O’Connor (pone.0310751.ref052) 2016; 315 E Molyneaux (pone.0310751.ref012) 2018 MK Jha (pone.0310751.ref022) 2023; 321 J Shen (pone.0310751.ref018) 2022; 13 Y Liu (pone.0310751.ref043) 2021; 61 DT Monks (pone.0310751.ref040) 2022; 22 MJ Page (pone.0310751.ref026) 2021; 88 GH Guyatt (pone.0310751.ref030) 2011; 64 L. Lv (pone.0310751.ref041) 2015; 21 BJ Shea (pone.0310751.ref027) 2009; 62 GH Guyatt (pone.0310751.ref029) 2008; 336 X Liu (pone.0310751.ref002) 2022; 31 J Yao (pone.0310751.ref033) 2020; 10 K. Hashimoto (pone.0310751.ref016) 2019; 73 W-S Wu (pone.0310751.ref050) 2023; 31 J Corcoran (pone.0310751.ref003) 2022 HT Chen (pone.0310751.ref031) 2024; 110 J Ge (pone.0310751.ref047) 2019; 39 Y Xu (pone.0310751.ref035) 2017; 295 A Roddy Mitchell (pone.0310751.ref005) 2023; 80 Y Alnefeesi (pone.0310751.ref015) 2022; 151 J Gibson (pone.0310751.ref056) 2009; 119 H Asare (pone.0310751.ref008) 2022; 181 QR Liu (pone.0310751.ref045) 2023; 339 DJ Fu (pone.0310751.ref021) 2023; 23 W Wang (pone.0310751.ref037) 2023; 102 X Liu (pone.0310751.ref044) 2013; 34 Y Zhou (pone.0310751.ref059) 2019; 19 RS McIntyre (pone.0310751.ref014) 2021; 178 Q Li (pone.0310751.ref020) 2022; 310 I Turkoz (pone.0310751.ref024) 2023; 323 SQ Yang (pone.0310751.ref019) 2023; 339 A Reif (pone.0310751.ref023) 2023; 389 P Kettunen (pone.0310751.ref007) 2014; 14 Xu Z-x Sun S-s (pone.0310751.ref049) 2023; 29 W Wang (pone.0310751.ref036) 2022; 101 O Akeju (pone.0310751.ref058) 2017; 44 Z. Luo (pone.0310751.ref042) 2019; 41 S Li (pone.0310751.ref060) 2024; 351 M Alipoor (pone.0310751.ref048) 2021; 14 J Guo (pone.0310751.ref034) 2023 K. Hashimoto (pone.0310751.ref054) 2020; 177 M Necho (pone.0310751.ref004) 2020 J Shi (pone.0310751.ref039) 2020; 36 DE Stewart (pone.0310751.ref006) 2019; 70 H Bolak Boratav (pone.0310751.ref053) 2016; 56 JVE Brown (pone.0310751.ref013) 2021 F Yang (pone.0310751.ref051) 2023; 43 LM Howard (pone.0310751.ref001) 2014; 384 Q Zhang (pone.0310751.ref032) 2016; 31 D Kingston (pone.0310751.ref011) 2018; 13 Y Han (pone.0310751.ref046) 2022; 22 |
| References_xml | – volume: 8 start-page: 141 year: 2005 ident: pone.0310751.ref055 article-title: Review of screening instruments for postpartum depression publication-title: Arch Womens Ment Health doi: 10.1007/s00737-005-0096-6 – volume: 150 start-page: 782 year: 1987 ident: pone.0310751.ref057 article-title: Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale publication-title: Br J Psychiatry doi: 10.1192/bjp.150.6.782 – volume: 14 start-page: 87 year: 2021 ident: pone.0310751.ref048 article-title: The effect of ketamine on preventing postpartum depression publication-title: J Med Life doi: 10.25122/jml-2020-0116 – volume: 339 start-page: 815 year: 2023 ident: pone.0310751.ref045 article-title: Effects of perioperative use of esketamine on postpartum depression risk in patients undergoing cesarean section: A randomized controlled trial publication-title: J Affect Disord doi: 10.1016/j.jad.2023.07.103 – volume: 44 start-page: 178 year: 2017 ident: pone.0310751.ref058 article-title: Neural oscillations demonstrate that general anesthesia and sedative states are neurophysiologically distinct from sleep publication-title: Curr Opin Neurobiol doi: 10.1016/j.conb.2017.04.011 – volume: 102 start-page: e33086 year: 2023 ident: pone.0310751.ref037 article-title: Effect of pre-administration of esketamine intraoperatively on postpartum depression after cesarean section: A randomized, double-blinded controlled trial publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000033086 – volume: 56 start-page: 502 year: 2016 ident: pone.0310751.ref053 article-title: Postpartum depression and its psychosocial correlates: A longitudinal study among a group of women in Turkey publication-title: Women Health doi: 10.1080/03630242.2015.1101737 – volume: 366 start-page: l4898 year: 2019 ident: pone.0310751.ref028 article-title: RoB 2: a revised tool for assessing risk of bias in randomised trials publication-title: Bmj doi: 10.1136/bmj.l4898 – volume: 339 start-page: 333 year: 2023 ident: pone.0310751.ref019 article-title: Effects of different doses of esketamine intervention on postpartum depressive symptoms in cesarean section women: A randomized, double-blind, controlled clinical study publication-title: J Affect Disord doi: 10.1016/j.jad.2023.07.007 – volume: 70 start-page: 183 year: 2019 ident: pone.0310751.ref006 article-title: Postpartum Depression: Pathophysiology, Treatment, and Emerging Therapeutics publication-title: Annu Rev Med doi: 10.1146/annurev-med-041217-011106 – volume: 177 start-page: 113935 year: 2020 ident: pone.0310751.ref054 article-title: Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2020.113935 – volume: 14 start-page: 402 year: 2014 ident: pone.0310751.ref007 article-title: Is postpartum depression a homogenous disorder: time of onset, severity, symptoms and hopelessness in relation to the course of depression publication-title: BMC Pregnancy and Childbirth doi: 10.1186/s12884-014-0402-2 – start-page: 1 year: 2023 ident: pone.0310751.ref034 article-title: Efficacy and safety of perioperative application of ketamine on postoperative depression: A meta-analysis of randomized controlled studies publication-title: Molecular Psychiatry – volume: 119 start-page: 350 year: 2009 ident: pone.0310751.ref056 article-title: A systematic review of studies validating the Edinburgh Postnatal Depression Scale in antepartum and postpartum women publication-title: Acta Psychiatr Scand doi: 10.1111/j.1600-0447.2009.01363.x – volume: 64 start-page: 1311 year: 2011 ident: pone.0310751.ref030 article-title: GRADE guidelines: 9. Rating up the quality of evidence publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2011.06.004 – volume: 151 start-page: 693 year: 2022 ident: pone.0310751.ref015 article-title: Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis publication-title: J Psychiatr Res doi: 10.1016/j.jpsychires.2022.04.037 – start-page: 4 year: 2018 ident: pone.0310751.ref012 article-title: Antidepressants for preventing postnatal depression publication-title: Cochrane Database Syst Rev – volume: 29 start-page: 1395 year: 2023 ident: pone.0310751.ref049 article-title: Sun H. Effects of intravenous infusion of esketamine on analgesia and postpartum antidepressant after cesarean section publication-title: Journal of Hainan Medical University – start-page: 13 year: 2020 ident: pone.0310751.ref004 article-title: A systematic review and meta-analysis of depression in postpartum women in a low-income country; Ethiopia, 2020 publication-title: The Open Public Health Journal – volume: 228 start-page: 143 year: 2018 ident: pone.0310751.ref009 article-title: Effect of maternal postpartum depression on offspring’s growth publication-title: J Affect Disord doi: 10.1016/j.jad.2017.12.013 – volume: 80 start-page: 425 year: 2023 ident: pone.0310751.ref005 article-title: Prevalence of Perinatal Depression in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis publication-title: JAMA Psychiatry doi: 10.1001/jamapsychiatry.2023.0069 – volume: 88 start-page: 105906 year: 2021 ident: pone.0310751.ref026 article-title: The PRISMA 2020 statement: An updated guideline for reporting systematic reviews publication-title: Int J Surg doi: 10.1016/j.ijsu.2021.105906 – volume: 323 start-page: 115165 year: 2023 ident: pone.0310751.ref024 article-title: Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray publication-title: Psychiatry Res doi: 10.1016/j.psychres.2023.115165 – volume: 61 start-page: 84 year: 2021 ident: pone.0310751.ref043 article-title: Effects of esketamine combined with hydromorphone on analgesia and postpartum depression after cesarean section publication-title: Shandong Medical Journal – volume: 22 start-page: 786 year: 2022 ident: pone.0310751.ref040 article-title: A randomized feasibility pilot-study of intravenous and subcutaneous administration of ketamine to prevent postpartum depression after planned cesarean delivery under neuraxial anesthesia publication-title: BMC Pregnancy Childbirth doi: 10.1186/s12884-022-05118-8 – volume: 22 start-page: 49 year: 2022 ident: pone.0310751.ref046 article-title: S-ketamine as an adjuvant in patient-controlled intravenous analgesia for preventing postpartum depression: a randomized controlled trial publication-title: BMC Anesthesiol doi: 10.1186/s12871-022-01588-7 – start-page: 1 year: 2023 ident: pone.0310751.ref010 article-title: The trajectory of maternal perinatal depressive symptoms predicts executive function in early childhood publication-title: Psychol Med – volume: 384 start-page: 1775 year: 2014 ident: pone.0310751.ref001 article-title: Non-psychotic mental disorders in the perinatal period publication-title: Lancet doi: 10.1016/S0140-6736(14)61276-9 – volume: 62 start-page: 1013 year: 2009 ident: pone.0310751.ref027 article-title: AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2008.10.009 – volume: 14 start-page: 961 year: 2023 ident: pone.0310751.ref025 article-title: Predictive values of metabolic score for insulin resistance on risk of major adverse cardiovascular events and comparison with other insulin resistance indices among Chinese with and without diabetes mellitus: results from the 4C cohort study publication-title: Journal of Diabetes Investigation doi: 10.1111/jdi.14024 – volume: 13 start-page: 1038379 year: 2022 ident: pone.0310751.ref018 article-title: The effect of low-dose esketamine on pain and post-partum depression after cesarean section: A prospective, randomized, double-blind clinical trial publication-title: Front Psychiatry doi: 10.3389/fpsyt.2022.1038379 – volume: 39 start-page: 501 year: 2023 ident: pone.0310751.ref038 article-title: Effects of different doses of esketamine on analgesia and postpartum depression after cesarean section publication-title: Clinical Anesthesiology – volume: 110 start-page: 1113 year: 2024 ident: pone.0310751.ref031 article-title: Efficacy of electroacupuncture in improving postoperative ileus in patients receiving colorectal surgery: a systematic review and meta-analysis publication-title: Int J Surg – volume: 43 start-page: 253 year: 2023 ident: pone.0310751.ref051 article-title: Effects of intervention with esketamine after cesarean section on postpartum depression, Treg cell percentage, and IL-10 expression publication-title: Journal of Nantong University (Medical Sciences) – volume: 178 start-page: 383 year: 2021 ident: pone.0310751.ref014 article-title: Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2020.20081251 – year: 2021 ident: pone.0310751.ref013 article-title: Antidepressant treatment for postnatal depression publication-title: Cochrane Database of Systematic Reviews – volume: 336 start-page: 924 year: 2008 ident: pone.0310751.ref029 article-title: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations publication-title: Bmj doi: 10.1136/bmj.39489.470347.AD – volume: 315 start-page: 388 year: 2016 ident: pone.0310751.ref052 article-title: Primary Care Screening for and Treatment of Depression in Pregnant and Postpartum Women: Evidence Report and Systematic Review for the US Preventive Services Task Force publication-title: Jama doi: 10.1001/jama.2015.18948 – volume: 31 start-page: 1812 year: 2023 ident: pone.0310751.ref050 article-title: Effects of esketamine combined with nalbuphine for patient-controlled intravenous analgesia in women: evaluation of analgesia, recovery quality, and postpartum depression following cesarean section publication-title: Chin J Fam Plann – start-page: 1 year: 2022 ident: pone.0310751.ref003 article-title: Prevalence of depression during pregnancy and postpartum periods in low-income women in developed countries publication-title: Journal of Public Health – volume: 181 start-page: 979 year: 2022 ident: pone.0310751.ref008 article-title: Maternal postpartum depression in relation to child undernutrition in low- and middle-income countries: a systematic review and meta-analysis publication-title: European Journal of Pediatrics doi: 10.1007/s00431-021-04289-4 – volume: 36 start-page: 2956 year: 2020 ident: pone.0310751.ref039 article-title: Study on the prophylactic effect of low-dose ketamine on postpartum depression after cesarean section publication-title: Journal of Modern Medicine & Health – volume: 101 start-page: e32010 year: 2022 ident: pone.0310751.ref036 article-title: Effects of esketamine on analgesia and postpartum depression after cesarean section: A randomized, double-blinded controlled trial publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000032010 – volume: 41 start-page: 1774 year: 2019 ident: pone.0310751.ref042 article-title: Effect of sufentanil combined with low-dose ketamine applied to analgesia after cesarean section publication-title: Guangxi Medical Journal – volume: 310 start-page: 114396 year: 2022 ident: pone.0310751.ref020 article-title: A single intravenous administration of a sub-anesthetic ketamine dose during the perioperative period of cesarean section for preventing postpartum depression: A meta-analysis publication-title: Psychiatry Res doi: 10.1016/j.psychres.2022.114396 – volume: 351 start-page: 720 year: 2024 ident: pone.0310751.ref060 article-title: Effects of ketamine and esketamine on preventing postpartum depression after cesarean delivery: A meta-analysis publication-title: J Affect Disord doi: 10.1016/j.jad.2024.01.202 – volume: 21 start-page: 4570 year: 2015 ident: pone.0310751.ref041 article-title: Effect of maternal pre-injection of low dose ketamine on postpartum depression score in cesarean section publication-title: Medical Recapitulate – volume: 321 start-page: 153 year: 2023 ident: pone.0310751.ref022 article-title: Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability publication-title: J Affect Disord doi: 10.1016/j.jad.2022.10.020 – volume: 13 start-page: e0195365 year: 2018 ident: pone.0310751.ref011 article-title: Trajectories of maternal depressive symptoms during pregnancy and the first 12 months postpartum and child externalizing and internalizing behavior at three years publication-title: PLoS One doi: 10.1371/journal.pone.0195365 – volume: 23 start-page: 587 year: 2023 ident: pone.0310751.ref021 article-title: Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality publication-title: BMC Psychiatry doi: 10.1186/s12888-023-05017-y – volume: 34 start-page: 1917 year: 2013 ident: pone.0310751.ref044 article-title: Effect of pre-administration of low-dose ketamine on Edinburgh Postnatal Depression Scale scores in women after cesarean section publication-title: Guangdong Medical Journal – volume: 389 start-page: 1298 year: 2023 ident: pone.0310751.ref023 article-title: Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression publication-title: N Engl J Med doi: 10.1056/NEJMoa2304145 – volume: 31 start-page: 502 year: 2016 ident: pone.0310751.ref032 article-title: Effect of low-dose ketamine on prevention of depression after cesarean section publication-title: Journal of North Sichuan Medical College – volume: 295 start-page: 1167 year: 2017 ident: pone.0310751.ref035 article-title: Single bolus low-dose of ketamine does not prevent postpartum depression: a randomized, double-blind, placebo-controlled, prospective clinical trial publication-title: Arch Gynecol Obstet doi: 10.1007/s00404-017-4334-8 – volume: 39 start-page: 810 year: 2019 ident: pone.0310751.ref047 article-title: Effect of ketamine on analgesia and postpartum depression after cesarean section publication-title: J Xuzhou Med Univ – volume: 31 start-page: 2665 year: 2022 ident: pone.0310751.ref002 article-title: Prevalence and Risk Factors of Postpartum Depression in Women: A Systematic Review and Meta-analysis publication-title: Journal of Clinical Nursing doi: 10.1111/jocn.16121 – volume: 73 start-page: 613 year: 2019 ident: pone.0310751.ref016 article-title: Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective publication-title: Psychiatry Clin Neurosci doi: 10.1111/pcn.12902 – volume: 19 start-page: 1 year: 2019 ident: pone.0310751.ref059 article-title: Efficacy and safety of prophylactic use of ketamine for prevention of postanesthetic shivering: a systematic review and meta analysis publication-title: BMC anesthesiology doi: 10.1186/s12871-019-0910-8 – volume: 10 start-page: e01715 year: 2020 ident: pone.0310751.ref033 article-title: Intraoperative ketamine for reduction in postpartum depressive symptoms after cesarean delivery: A double-blind, randomized clinical trial publication-title: Brain and Behavior doi: 10.1002/brb3.1715 – volume: 279 start-page: 252 year: 2019 ident: pone.0310751.ref017 article-title: Prophylactic use of ketamine reduces postpartum depression in Chinese women undergoing cesarean section(✰) publication-title: Psychiatry Res doi: 10.1016/j.psychres.2019.03.026 |
| SSID | ssj0053866 |
| Score | 2.4727013 |
| SecondaryResourceType | review_article |
| Snippet | Postpartum depression (PPD) is a major mental health issue affecting 10%-15% of women globally. This meta-analysis synthesized updated evidence on... Objective Postpartum depression (PPD) is a major mental health issue affecting 10%-15% of women globally. This meta-analysis synthesized updated evidence on... ObjectivePostpartum depression (PPD) is a major mental health issue affecting 10%–15% of women globally. This meta-analysis synthesized updated evidence on... ObjectivePostpartum depression (PPD) is a major mental health issue affecting 10%-15% of women globally. This meta-analysis synthesized updated evidence on... Objective Postpartum depression (PPD) is a major mental health issue affecting 10%–15% of women globally. This meta-analysis synthesized updated evidence on... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0310751 |
| SubjectTerms | Anesthesia Antidepressants Bias Biology and Life Sciences Depression, Postpartum - prevention & control Dosage Dosage and administration Drug dosages Female Humans Intervention Ketamine Ketamine - administration & dosage Ketamine - therapeutic use Medicine and Health Sciences Mental depression Meta-analysis People and Places Perioperative care Perioperative Care - methods Pharmacology, Experimental Physical Sciences Physiological aspects Postpartum Postpartum depression Prevention Randomized Controlled Trials as Topic Reliability Research and Analysis Methods Science Policy Sequential analysis Social Sciences Subgroups Testing |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQnrggyquBAgYhAYe0GzuxHW4LoipIPAQU9Rb5WRDdJCLZA3-DX8xM4o0aVKkcuEXriXd3Zjz-nMx8Q8gTByBcOibSwJxLc2-L1DBmU-l5CNYprjU-h3z3Xhwd529PipNzrb4wJ2ykBx4Vd5Bz7bUS1jDu89wrrZQTPnPM62UIQwU1gz1ve5gaYzCsYiFioRyX2UG0y37b1H4fyTBlkc02ooGvf4rKi_as6S6CnH9nTp7big6vk2sRQ9LV-Nt3yBVf3yA7cZV29Fmkkn5-k_z-CA7WtH6k96Z6xpRLm0C7jUk1RDuAgTAZ_eF7vUbmDN9tLymgWtpGoqf6lLZN17egts2aTlm0Ne1-rdu-WXcv6IoOjUDomKPd4-UapoJvGdlPbpHjw9dfXh2lsQtDakXJ-9SqpUHSQCOdMEtvNcQBwwtpvPJL7yRADBlK7QvnSiac5UYDJNOCeS9tEXJ-myxq0PsuoVoE7vEZhlF5Lo3TpihLz0LmQsEcyxPCtyapbKQox04ZZ9Xw3k3CUWXUcIWGrKIhE5JOd7UjRccl8i_R2pMsEmwPH4DbVdHtqsvcLiEP0VeqsVp1ChPVSmUCgmbBZEIeDxJIslFjFs-p3nRd9ebD138Q-vxpJvQ0CoUG1GF1rJyA_4TkXTPJvZkkhAo7G95Fz95qpas4oL0yV3CKhTu33n7x8KNpGCfFzLzaNxuU4fgym3GRkDvj4pg0y8sCzwssIWq2bGaqn4_U378NHOfIAYU9tO7-D2PdI1cZYFEsIc3UHln0Pzf-PmDJ3jwYwsYfrJV6IQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lj9MwELagXLggltcWFjAICThkt7UT2-GCCmK1IPEQsKi3yM-C2CZhkx74G_xiZhI3ELQCblE9cdsZz_izPf6GkAcOQLh0TCSBOZek3maJYcwm0vMQrFNca9yHfP1GHB2nr5bZMm64NTGtchsTu0DtKot75AccJqY8VQC4n9bfEqwahaersYTGeXIBqcswpUsuhwUX-LIQ8bocl_ODaJ39uir9PlJiymw-mo461v4hNk_qk6o5C3j-mT_524R0eJlcikiSLnrT75BzvrxCdqKvNvRRJJR-fJX8eAfDrKp9T_JN9Ygvl1aBNhuTaIh5AAahM_rVt3qN_Bm-2T5SwLa0jnRP5YrWVdPWMOo2azrk0pa0-b6u22rdPKEL2pUDoX2mdouPa-gKvqXnQLlGjg9ffHx-lMRaDIkVOW8Tq2YGqQONdMLMvNUQDQzPpPHKz7yTADRkyLXPnMuZcJYbDcBMC-a9tFlI-XUyKUHvu4RqEbjHnQyj0lQap02W556FuQsZcyydEr41SWEjUTnWyzgputM3CQuWXsMFGrKIhpySZHir7ok6_iH_DK09yCLNdvdBdboqotcWKddeK2EN4z5NvdJKOeHnjnk9C4FDJ3dxrBT9ndUhWBQLNRcQOjMmp-R-J4FUGyXm8qz0pmmKl28__YfQh_cjoYdRKFSgDqvj_Qn4T0jhNZLcG0lCwLCj5l0c2VutNMUv14I3t6P97OZ7QzN2ivl5pa82KMPxSJtxMSU3eucYNMvzDFcNbErUyG1Gqh-3lF8-d0znyASFlbRu_v133SIXGWBNvCI6V3tk0p5u_G3Aiq250wWEnxCYcIg priority: 102 providerName: ProQuest |
| Title | Perioperative administration of sub-anesthetic ketamine/esketamine for preventing postpartum depression symptoms: A trial sequential meta-analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39556562 https://www.proquest.com/docview/3129948960 https://www.proquest.com/docview/3130203236 https://pubmed.ncbi.nlm.nih.gov/PMC11573214 https://doaj.org/article/43aea86cb23e44e8a88d6e1d2ea0ff31 http://dx.doi.org/10.1371/journal.pone.0310751 |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdG98ILYnytMIpBSMBDqsZOYgcJoW7aGEgb06Cob5EdOwXRJqFJJfZv8Bdzly8RVMReoqg-u8r57vzz1-8IeW4AhAvDAidhxjiejX1HMxY7wvIkiY3kSuE65Nl5cDrzPsz9-Q5pc7Y2Ciy2Tu0wn9RsvRz__HH1Fhz-TZW1QbhtpXGepXaMVJcC71Tvwtgk0FXPvG5fAby72r1E1OIEbMKby3T_aqU3WFWc_l3kHuTLrNgGS_8-XfnHcHVym9xqcCad1oaxR3ZseofsNZ5c0JcN3fSru-TXBRghfHRNAU5Vj02XZgktNtpREBEBKkJj9Lst1QrZNWzRvlJAvjRvyKDSBc2zoszBJjcr2p20TWlxtcrLbFW8plNaJQuh9TnuEl9X0BT8S82Qco_MTo4_H506TaYGJw5CXjqxnGgkFtTCBHpiYwWxQnNfaCvtxBoBMEQkobK-MSELTMy1AtimAmatiP3E4_fJIAW97xOqgoRbXOfQ0vOENkr7YWhZ4prEZ4Z5Q8LbLonihsYcs2kso2pvTsB0ptZwhB0ZNR05JE5XK69pPP4jf4i93ckiCXf1Q7ZeRI1PRx5XVskg1oxbz7NSSWkC6xpm1SRJODTyBG0lqm-0dqEkmko3gMDqMzEkzyoJJOJI8aTPQm2KInr_8cs1hD5d9oReNEJJBuqIVXO7Ar4JCb56kgc9SQgnca94Hy271UoRcUCEoSdhpgs1W2vfXvy0K8ZG8fRearMNynDc8GY8GJIHtXN0muWhj3MKNiSy5zY91fdL0m9fKx505InCPFsPr6PFR-QmAzyK10hdeUAG5XpjHwOeLPWI3BBzAU955OLz5N2I7B4en19cjqoVmlEVQn4DCRp_RQ |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKOcAFUV5dKNQgEHBIu7ETO0FCqDyqXfoAQYt6C36lILpJaLJC_Rv8EH4jM3lBUAVceovWE-_uzHhmbM98Q8h9C0G4tEx4KbPWC5wJPc2Y8aTjaWpsxJXCc8idXTHZD14fhAcL5EdXC4NplZ1NrA21zQ2eka9zcExxEEHA_az46mHXKLxd7VpoNGqx5U6-wZatfDp9CfJ9wNjmq70XE6_tKuAZEfPKM9FYIwiellbosTMK9FrzUGoXubGzElymTGPlQmtjJqzhWkGIoQRzTpowDTjMe46cB8c7xhUlD_oNHtgOIdryPC799VYb1oo8c2sIwSlDf-D-6i4BvS9YLI7y8rRA9898zd8c4OZlcqmNXOlGo2pLZMFlV8hSaxtK-qgFsH58lXx_C2qdF64BFadqgM9L85SWc-0psLEQfMJk9Iur1AzxOlzZPVKIpWnRwktlh7TIy6oALZ_PaJ-7m9HyZFZU-ax8Qjdo3X6ENpnhFT7OYCr4lgZz5RrZPxMpXSeLGfB9mVAlUu7w5ERHQSC1VTqMY8dS36YhsywYEd6JJDEtMDr25zhK6ts-CRukhsMJCjJpBTkiXv9W0QCD_IP-OUq7p0VY7_qD_Pgwaa1EEnDlVCSMZtwFgYtUFFnhfMucGqcph0lWUVeSpka2N07JRuQLMNUhkyNyr6ZAaI8Mc4cO1bwsk-mbD_9B9P7dgOhhS5TmwA6j2noN-E8IGTagXBlQgoEyg-Fl1OyOK2XyaynDm522nz58tx_GSTEfMHP5HGk4XqEzLkbkRrM4es7yOMRdChuRaLBsBqwfjmSfP9XI6og8hZ27bv79d62SC5O9ne1ke7q7dYtcZBDnYnmqH62Qxep47m5DnFrpO7VxoOTjWVujn3IZrr8 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtQwELXKIiFeEOXWhUINAgEPaTd2YidICBVK1VIoFaWob8G3LIhuEpqsUH-Dz-HrmMkNgirgpW_ReuLdnRkfj-3xGULuWwjCpWXCS5m1XuBM6GnGjCcdT1NjI64U7kO-2RVbB8Grw_Bwgfzo7sJgWmWHiTVQ29zgHvkah4kpDiIIuNfSNi1ib2PzWfHVwwpSeNLaldNoXGTHnXyD5Vv5dHsDbP2Asc2X719seW2FAc-ImFeeiSYaCfG0tEJPnFHg45qHUrvITZyVMH3KNFYutDZmwhquFYQbSjDnpAnTgEO_58h5yUMfx5g87Bd7gCNCtFf1uPTXWs9YLfLMrSIdpwz9wVRYVwzo54VRcZSXpwW9f-Zu_jYZbl4ml9oolq43brdIFlx2hSy2OFHSRy2Z9eOr5PseuHheuIZgnKoBVy_NU1rOtacAbyEQhc7oF1epGXJ3uLJ7pBBX06KlmsqmtMjLqgCPn89on8eb0fJkVlT5rHxC12ldioQ2WeIVPs6gK_iWhn_lGjk4EytdJ6MM9L5EqBIpd7iLoqMgkNoqHcaxY6lv05BZFowJ70ySmJYkHWt1HCX1yZ-ExVKj4QQNmbSGHBOvf6toSEL-If8crd3LIsV3_UF-PE1axEgCrpyKhNGMuyBwkYoiK5xvmVOTNOXQyQr6StLcl-2BKlmPfAGwHTI5JvdqCaT5yHDATNW8LJPttx_-Q2j_3UDoYSuU5qAOo9q7G_CfkD5sILk8kASwMoPmJfTsTitl8mtYw5udt5_efLdvxk4xNzBz-RxlOB6nMy7G5EYzOHrN8jjEFQsbk2gwbAaqH7Zknz_VLOvIQoVVvG7-_XetkAuAQ8nr7d2dW-Qig5AXb6r60TIZVcdzdxtC1krfqbGBko9nDUY_AU5OsvU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Perioperative+administration+of+sub-anesthetic+ketamine%2Fesketamine+for+preventing+postpartum+depression+symptoms%3A+A+trial+sequential+meta-analysis&rft.jtitle=PloS+one&rft.au=Hung%2C+Kuo-Chuan&rft.au=Kao%2C+Chia-Li&rft.au=Lai%2C+Yi-Chen&rft.au=Chen%2C+Jen-Yin&rft.date=2024-11-18&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=19&rft.issue=11&rft.spage=e0310751&rft_id=info:doi/10.1371%2Fjournal.pone.0310751&rft.externalDBID=IOV&rft.externalDocID=A816730527 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |